Probatebeta
Target

FGFR4

Fibroblast growth factor receptor 4

As of the edition of 20 October 2026, FGFR4 (fibroblast growth factor receptor 4, UniProt P22455) has 20 drugs tested at it and 20 companies on the list, 5 on route A and 4 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P22455
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
55
Disease areas
Cancer; Lungs and airways; Digestive system; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue; Hormones; Inherited and neonatal
Registered trials of its drugs
370

Drugs at this target

StatusCount
Marketed4
Active2
Went quiet4
Stopped6
Status not established4
Total20
DrugStatusFurthest phaseUS protection
NintedanibMarketedPhase 4Ends 2027
ErdafitinibMarketedPhase 3Ends 2033
InfigratinibMarketedPhase 3Ends 2029
FutibatinibMarketedPhase 3Ends 2036
FexagratinibActivePhase 3none listed
BrivanibStoppedPhase 3none listed
AldaferminStoppedPhase 3none listed
RogaratinibStoppedPhase 3none listed
XL-999Went quietPhase 2none listed
ENMD-981693Went quietPhase 2none listed
Brivanib alaninateStoppedPhase 2none listed
DerazantinibStoppedPhase 2none listed

12 of 20 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A5
Route B4
Engaged3
Undetermined8
Total on the list20
Three companies on route A or B, with the route only
CompanyRoute
AstraZenecaRoute A
Helsinn HealthcareRoute B
TaihoRoute B

The other 17 companies at FGFR4

In the product

20 companies in all; 17 are not named here, and no score is.

See the 20 companies at FGFR4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at FGFR4

Other targets in cancer

Companies holding approvals at FGFR4